Table 2.
Article Author | Fluid Sampled | Model Species | Fluid Analysis Method | Sample size(s) |
---|---|---|---|---|
Rockel et al., 2018 8 | Plasma | Human | LC-MS/MS | OA=152, HC=194 |
Steventon et al., 2012 9 | Plasma | Human | RP-HPLC with fluorescence detection | HC=100 |
Smilde et al., 2005 10 | Urine | Guinea Pig | H1 NMR | OA=12, HC=6 |
Carlson et al., 2018 11 | Synovial Fluid | Human | LC-MS | OA=5, HC=5 |
Loeser et al., 2016 12 | Urine | Human | H1 NMR, ELISA, automated immunoanalyzer | OA1=22, OA2=22 |
Carlson et al., 2019 13 | Synovial Fluid | Human | LC-MS | OA GI-II=55, OA GIII-IV=17, HC=7 |
Thompson et al., 2011 14 | Serum | Human | FI-ESI-MS | OA=40 |
Costello et al., 2020 15 | Plasma | Human | UPLC-MS, FI-ESI-MS | OA=704 |
Hu et al., 2020 16 | Synovial Fluid | Rabbit | UPLC-MS | OA=12, HC=12 |
Kang et al., 2015 17 | Synovial Fluid | Human | UPLC-QTOF-MS | OA=10 |
Jiang et al., 2018 18 | Urine | Rat | GC-TOF-MS | OA=8, HC=8 |
Maher et al., 2012 19 | Serum | Ovine | H1 NMR | Oam=24, HC=12 |
Datta et al., 2017 20 | Plasma | Mouse | RP-LC-MS-MS | n=undefined |
Adams et al., 2014 21 | Synovial Fluid | Human | LC-MS, GC-MS, ELISA | OA=20, HC=20 |
Huang et al., 2020 22 | Plasma | Human | GC-QTOF-MS | OA=12, HC=20 |
Senol et al., 2019 23 | Serum | Human | LC-QTOF-MS-MS | OKOA=14, NOKOA=14, HC=15 |
Pousinis et al., 2020 24 | Plasma | Mouse | UHPLC-HR-MS | OA=8, HC=7 |
Zhang et al., 2016 25 | Plasma | Human | TQ-UPLC-MS | DC-TKR=64, DC-NTKR=45, RC-TKR=72, RC-NTKR=76, LC-TKR=36, LC-NTKR=122 |
Tootsi et al., 2018 26 | Serum | Human | UPLC-MS | OA=70, HC=82 |
Mickiewicz et al., 2015 27 | Synovial Fluid | Human | H1 NMR, GC-MS | OA=55, HC=13 |
Mickiewicz et al., 2015 28 | Synovial Fluid | Ovine | H1 NMR | OA=9, HC=9 |
Abdelrazig et al., 2021 29 | Urine | Human | LC-HR-MS | OA=74, HC=68 |
Liu et al., 2021 30 | Plasma | Human | UPLC-MS, FI-ESI-MS | n=610 |
Yin et al., 2017 31 | Urine | Rat | GC-MS | OA=8, HC=8 |
Zhang et al., 2016 32 | Plasma | Human | TQ-UPLC-MS | DC-OA=64, DC-HC=45, RC-OA=72, RC-HC=76 |
Zhang et al., 2016 33 | Synovial Fluid, Plasma | Human | TQ-UPLC-MS | DC-OA=54, DC-HC=30, RC-OA=72, RC-HC=71 |
Maerz et al., 2018 34 | Serum | Rat | H1 NMR, LC-MS-MS | OA=18, HC=18 |
Hu et al., 2016 35 | Plasma | Human | TQ-UPLC-MS | DC-OA=64, DC-HC=45, RC-OA=72, RC-HC=76 |
Chen et al., 2018 36 | Serum | Human | TQ-UPLC-MS | OA=32, HC=35 |
Zhai et al., 2021 37 | Plasma | Human | TQ-UPLC-MS | Oaup=57, Oanup=206, Oabp=177, Oanbp=116 |
Zhai et al., 2010 38 | Serum | Human | LC-MS-MS | DC-OA=123, DC-HC=299, RC-OA=76, RC-HC=100 |
Zhang et al., 2015 39 | Serum | Human | UPLC-MS | OA=40, HC=20 |
Kosinska et al., 2014 40 | Synovial Fluid | Human | FI-ESI-MS-MS, LC-MS-MS | eOA=17, lOA=13, HC=9 |
Hügle et al., 2012 41 | Synovial Fluid | Human | H1 NMR | OA=15 |
He et al., 2021 42 | Plasma | Human | GC-MS | OA=12, HC=12 |
Li et al., 2009 43 | Urine | Human | GC-MS | OA=37, HC=37 |
Zhao et al., 2021 44 | Serum | Rat | LC-MS | OA=6, HC=6 |
Wallace et al., 2022 45 | Synovial Fluid, Serum | Mouse | LC-MS | OA=8, HC=4 |
Hahn et al., 2021 46 | Synovial Fluid | Mouse | LC-MS | OA=9, HC=9 |
Abshirini et al., 2021 47 | Plasma | Rats | LC-MS | OA=13, HC=11 |
Xiao et al., 2022 48 | Serum | Rabbit | LC-MS-MS | OA=6, HC=3 |
Pertusa et al., 2022 49 | Serum | Human | H1-NMR | OA=23, HC =53 |
Nieminen et al., 2022 50 | Synovial Fluid | Human | UHPLC-QTOF-MS | OA=10, HC=5 |
General characteristics of each study include first author and date of publication, fluid sampled, model species, method of fluid analysis for metabolomics, and sample sizes. LC=Liquid chromatography, MS=Mass spectrometry, RP=Reversed phase, HPLC=High-performance liquid chromatography, H1-NMR=Proton Nuclear Magnetic Resonance, ELISA=Enzyme-linked immunosorbent assay, FI-ESI=Flow-injection electrospray ionization, QTOF=quadrupole time-of-flight, GC=Gas chromatography, TOF=Time-of-flight, TQ=Triple quadrupole, HR=High resolution, UPLC=Ultra performance liquid chromatography, OA=Osteoarthritis subjects, HC=Healthy control for comparison, OA1=Evidence of OA progression on radiographic findings 18 months from baseline, OA2=No evidence of OA progression on radiographic findings 18 months from baseline, OA GI-II=OA grades I-II using Outerbridge scale scoring, OA GIII-IV=OA grades III-IV using Outerbridge scale scoring, Oam=Models with OA induced by meniscal destabilization (MD, 12) or anterior cruciate ligament transection (ACLT, 12), OKOA=Knee OA and obesity (BMI≥30), NOKOA=Knee OA without obesity (BMI<30), TKR=Total knee replacement, NTKR=No total knee replacement performed, DC=Discovery cohort subjects, RC=Replication cohort subjects, LC=Longitudinal study cohort subjects, Oaup=OA patients with radiographic evidence of unilateral knee OA progression, Oanup=OA patients without radiographic evidence of unilateral knee OA progression, Oabp=OA patients with radiographic evidence of bilateral knee OA progression, Oanbp=OA patients without evidence of bilateral knee OA progression, eOA=OA with Outerbridge classification scale score ≤ 2, lOA=OA with Outerbridge classification scale score >2.